April 21, 2021 5:54pm

Cell and gene therapy sector equities are popping from being oversold, I’m still waiting for “them” to have an ignition factor of their own making

Pre-open indication performance: 3 HITs and 5 Miss (but, you made a profit)

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing! 

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors


The Dow closed UP +316.01 points (+0.93%); the S&P closed UP +38.48 points (+0.93%) while the Nasdaq closed UP +163.95 points (+1.19%)



Indexes and cell and gene therapy stocks rose on Wednesday as equities tried to recover from two straight days of losses.

The small-cap Russell 2000 rallied 2.4%, bringing its 2021 gains to more than 13%.

The Cboe Volatility Index, aka the VIX or the fear gauge fell to 17.50 on Wednesday from Tuesday’s above 18.68.


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions

  • Wednesday opened negative at 10/23, 1 flat and 1 acquired, moved positive at 11 a.m. at 26/7, 1 flat and 1 acquired, stayed the mid-day to 23/9, 2 flats and 1 acquired, closing positive at 30/3, 1 flat and 1 acquired;


RegMed Investors’ (RMi) pre-open: “what’s resonating? Sentiment ruled by algorithms and electronic trading.” … https://www.regmedinvestors.com/articles/11875


Pre-open indication results:  3 HITs < Biostage (BSTG -$0.00 at $1.00 with 250 shares traded); CRISPR Therapeutics (CRSP +$3.26), Ionis, Pharmaceuticals (IONS +$0.33) and 5 MISS < Adverum Biotechnologies (ADVM +$0.30), Editas Medicine (EDIT +$1.39), Global Blood Therapeutics (GBT +$1.02), Intellia Therapeutics (NTLA +$2.22), Vericel (VCEL +$0.11),     


There are clear winners and losers

Jumping with share pricing momentum:

  • Fate Therapeutics (FATE), Ultragenyx (RARE), Vericel (VCEL), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA) to name 5 of the 30 inclining of the 35 covered

Hammered in today’s market:

  • ReNeuron (RENE.L), MiMedx (MDXG), uniQure NV (QURE) to name 3 of the 3 declining of the 35 covered


Key metrics:

  • Sector volume was LOW with 4 of the 30-upside having higher than the 3-month average volume with the volume of 2 of 3 downside having higher than the 3-month average volume;
  • Wednesday’s percentage (%) of the 30-upside were +0.80% (IONS) to +12.98% (AGTC) while the 3-downside ranges from -0.40% (QURE) to -4.91% (RENE.L);


Wednesday’s (10 of 30) incline

  • Fate Therapeutics (FATE +$6.06 after Tuesday’s -$1.47 and Monday’s -$1.52);
  • Ultragenyx (RARE +$4.15);
  • Vericel (VCEL +$3.88 after Tuesday’s -$1.31 and Monday’s -$3.85);
  • CRISPR Therapeutics (CRSP +$3.26 after Tuesday’s +$6.63 on VRTX news and Monday’s -$3.52);
  • Intellia Therapeutics (NTLA +$2.22 after Tuesday’s +$0.08 and Monday’s -$3.12);
  • BioLife Solutions (BLFS +$1.56 after Tuesday’s -$1.20 and Monday’s -$1.46);
  • Alnylam Pharmaceuticals (ALNY +$1.50 after Tuesday’s -$1.37 and Monday’s -$1.48);
  • Editas Medicine (EDIT +$1.39 after Tuesday’s +$0.30);
  • Global Blood Therapeutics (GBT +$1.02 after Tuesday’s +$0.47);
  • AxoGen (AXGN +$1.01 after Tuesday’s +$0.55 and Monday’s -$1.05);

Wednesday’s (3 of 3) decliners:

  • ReNeuron (RENE.L -$6.50 after Tuesday’s flat);
  • MiMedx (MDXG -$0.33 after Tuesday’s -$0.51);
  • uniQure NV (QURE -$0.13 after Tuesday’s -$0.57 and Monday’s -$0.99);

Closing: 1 – Biostage (BSTG) and 1- Stemline Therapeutics (STML – acquired)


Sentiment and COVID-19:

  • Scientist who helped develop Pfizer-BioNTech Covid vaccine agrees third shot is needed as immunity wanes. Dr. Ozlem Tureci, co-founder and CMO of BioNTech, which developed a Covid vaccine with Pfizer, said she also expects people will need to get vaccinated against the coronavirus annually, like for the seasonal flu.

COVID Data Tracker <Million>:

  • Wednesday 31,6 M cases,
  • Wednesday’s death rate totaled 565,613 <Johns Hopkins University>
  • Wednesday vaccinations:  216 M



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB closed up to +1.97% and XBI closed up +3.49%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -1.18 points or -6.32% at 17.50

Upside volume: low

  • Wednesday: 4 out of the 30-upside had higher than the 3-month average volume;

Downside volume: low

  • Wednesday: 2 out of the 3-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Wednesday’s percentage (%) of the 30-upside were +0.80% (IONS) to +12.98% (AGTC) while the 3-downside ranges from -0.40% (QURE) to -4.91% (RENE.L);

April, the beginning of Q2/21:

Wednesday closed positive with 30 advancers, 3 decliners, 1 flat and 1 acquired


The BOTTOM LINE: After a two (2) session “drubbing”, the cell and gene therapy sector took-off to the upside from being oversold to reach the limits again of being overbought – how contrarian of me!

Investors or are the “machines algorithms” are buying dips?

Q1/21 earnings are being announced, Alnylam Pharmaceuticals (ANY) on Thursday, 4/29, Sage therapeutics (SAGE) on Tuesday, 5/4, AxoGen (AXGN) and Vericel (VCEL) on Wednesday, 5/5 and Athersys (ATHX) on Thursday, 5/6.

Sector momentum remains “sketchy” and these depressed pricing guarantees more uncertainty and risks but, some rebounds.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

My time frame of measurement is Friday to Friday and been proved right again, don’t get complacent …


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.